Institution Directory

Clinical trials at Stanford Medicine

Sites in Stanford & Palo Alto, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1353

Shown on this page

Current sort

Live official records

Conditions: Blood Loss, Surgical, Coagulation Disorder
Interventions: Reltodecacog alfa, Usual Pharmacological Care; Drug
Lead sponsor: VarmX B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 19
States / cities: Chandler, Arizona • Phoenix, Arizona • Stanford, California + 14 more

Conditions: Breast Cancer, Breast Neoplasms
Interventions: Disitamab vedotin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 128
States / cities: Daphne, Alabama • Foley, Alabama • Mobile, Alabama + 103 more

Conditions: Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Interventions: Bel-sar, Suprachoroidal Microinjector, Infrared Laser, Sham Infrared Laser, Sham Microinjector; Drug · Device
Lead sponsor: Aura Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 25
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 20 more

Conditions: Locally Advanced Pancreatic Adenocarcinoma
Interventions: Acoustic Cluster Therapy, Modified FOLFIRINOX; Combination Product · Drug
Lead sponsor: EXACT Therapeutics AS; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Scottsdale, Arizona • Stanford, California • Boston, Massachusetts + 4 more

Conditions: Desmoplastic Small Round Cell Tumor, Osteosarcoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Kidney Wilms Tumor, Recurrent Osteosarcoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Wilms Tumor, Wilms Tumor
Interventions: Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Trastuzumab Deruxtecan; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 39 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 32
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 27 more

Conditions: Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease, Steinert
Interventions: zeleciment basivarsen (DYNE-101), Placebo; Drug
Lead sponsor: Dyne Therapeutics; Industry
Eligibility: 16 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 14
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 11 more

Conditions: Renal Pelvis and Ureter Urothelial Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Pegfilgrastim, Therapeutic Conventional Surgery, Vinblastine Sulfate; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 257
States / cities: Kingman, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 197 more

Conditions: Chondral Defect, Osteochondritis Dissecans (OCD), Articular Cartilage Defect, Articular Cartilage Disorder of Knee
Interventions: MACI, microfracture; Biological · Procedure
Lead sponsor: Vericel Corporation; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 14
States / cities: Palo Alto, California • Sacramento, California • New Orleans, Louisiana + 9 more

Conditions: Pancreatic Cyst
Interventions: Not listed
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 10
States / cities: Scottsdale, Arizona • Stanford, California • New Haven, Connecticut + 7 more

Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neuroblastoma
Interventions: Biopsy Procedure, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Clinical Observation, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Magnetic Resonance Imaging, Ultrasound; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 18 Months
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 193
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 147 more

Conditions: Weight Regain, Weight Loss
Interventions: TORe with OverStitch, Intensive lifestyle modification; Device · Behavioral
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Irvine, California • Stanford, California • Jacksonville, Florida + 8 more

Conditions: Peripheral Arterial Hemorrhage, Trauma, GI Bleed, Ulcer, Hemorrhage
Interventions: Onyx™ Liquid Embolic System; Device
Lead sponsor: Medtronic Endovascular; Industry
Eligibility: 22 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Phoenix, Arizona • Irvine, California • Los Angeles, California + 17 more

About this Stanford Medicine institution page

What this page lists: ClinicalTrials.gov records that list Stanford Medicine in Stanford & Palo Alto, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Stanford Medicine

Filter and sort this campus

Live official records

Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass

Onyx™ Liquid Embolic IDE Clinical Study

About this Stanford Medicine institution page